Athletes may be tempted to genetically modify themselves to boost their performance far sooner than most people realize, researchers have warned.
The idea of sprinters and cyclists injecting themselves with genes coding for hormones that boost the number of red blood cells may sound far-fetched, and the results are uncertain. But some gene-therapy researchers and sports organizations believe that such a genetically modified athlete could mount the winner's podium at the 2008 Olympic Games in Beijing.
If such 'gene doping' did take place, it could be impossible to detect, warns Peter Schjerling, a molecular biologist at the Copenhagen Muscle Research Centre. Speaking at a conference on genes and sport at University College London on 30 November, Schjerling said that artificial genes "can and most likely will be abused by healthy athletes as a means of doping".
Schjerling is not the first to voice concern that unscrupulous athletes might exploit emerging gene-therapy techniques currently being developed to treat conditions such as kidney failure and anaemia. The International Olympic Committee has set up an advisory group on the matter, and says it is closely monitoring progress in gene therapy.
The World Anti-Doping Agency (WADA), a body coordinating a global campaign against the use of banned drugs in sport, is so concerned that it will hold a special conference to discuss the topic in But the institute's director, Chris Bostock, rejects the auditors' reports and denies that a mix-up occurred at the IAH.
An audit by the UK Accreditation Service (UKAS), based in Newbury, Berkshire, was made public on 30 November. It found that the IAH's record-keeping system fell short of accepted good practice, that "there was no formal documented quality system" and that this "was inadequate to give confidence in the chain of custody of the samples".
The London-based auditors Risk Solutions said that poor labelling could have allowed a mix up of the original 1990 sheep tissue samples with bovine samples that had been stored in the same freezer.
In a strong rebuttal, the institute said that it had in place "comprehensive and documented formal procedures" that met government standards.
Bostock says the audits were carried out hastily, and failed to inspect the institute's overall record-keeping system. "The audits fail to convince me that a mix-up occurred," says Bostock. The IAH is now completing an internal audit of the affair. EPO abuse is already thought to be rife in many sports, including cycling -a whole team was expelled from the 1998 Tour de France for using it -but tests have been developed that can find synthetic versions of the hormone injected into the body (see Nature 407, 124; 2000). Introducing the gene coding for EPO would circumvent the tests, however, because the extra hormone produced would effectively be endogenous.
The artificial gene could be delivered to the body in several different ways, experts say. Perhaps the easiest method would be to inject the DNA directly into the muscle. But more efficient techniques using viruses or modified cells from the patient are also being developed.
One problem that currently prevents the clinical use of these techniques is the difficulty of controlling which tissues receive the gene. Schjerling says this would be of little concern to an athlete who just wants a short-term boost in hormone levels. Equally, doubts about whether the genes would keep functioning over time would not concern someone preparing for a one-off event such as the Olympics.
Gene doping of this sort would be difficult to expose. "The DNA of the artificial gene itself can be detected," says Schjerling, "but this requires that the sequence be known and that a sample of the tissue containing it can be acquired."
Even if the risk of detection was small, the risk to the athlete's health probably would not be. This is where the almost fanatical desire of athletes to excel raises problems, according to some of those present at the London meeting. Several cyclists are already thought to have died from EPO use, as the marked increase in circulating red blood cells severely thickens the blood, increasing the risk of clots and strokes.
In animal studies undertaken at the Chiron Corporation in Emeryville, California (S. Zhou, J. E. Murphy, J. A. Escobedo & V. J. Dwarki, Gene Therapy 5, 665-670; 1998) , the levels of red blood cells in baboons given experimental EPO gene therapy rose so sharply (from 40 to 75% in 10 weeks) that their blood had to be regularly diluted to keep them alive.
Theodore Friedmann, director of the gene-therapy programme at the University of California, San Diego, and a member of the WADA health, medical and research committee, says gene doping may occur sooner than people think. "The technology needed for a rogue attempt won't take that long to develop," he says. Although he thinks it unlikely that any athlete has yet tried it, he adds: "We all think there will be an attempt to do so." Stem-cell pioneer John Gearhart has resigned from the editorial board of the biomedical journal that last month published a controversial paper claiming the creation of the first cloned human embryos.
Gearhart, a biologist at Johns Hopkins University in Baltimore, Maryland, says that in agreeing to publish the work, the journal had failed to uphold scientific standards.
The article appeared in the 26 November issue of the online journal e-biomed: The Journal of Regenerative Medicine (2, 25-31; 2001) , published by New York-based Liebert.
Using the technique that created Dolly the sheep, the researchers, led by Jose Cibelli and Michael West of Advanced Cell Technology, a biotechnology firm in Worcester, Massachusetts, transferred nuclei from human cumulus cells, which surround eggs after ovulation, to human eggs (see Nature 414, 477; 2001) . A few of the eggs divided once or twice before they died.
The company claimed that it had finally cloned humans, adding that it had achieved an important first step in developing a technology that will ultimately revolutionize medicine.
But Gearhart says: "I don't think they have come anywhere near the mark of what it would take to prove that claim." He argues that the research is lacking in several important respects, such as its failure to provide evidence that the DNA in the dividing eggs actually came from the donor cell, or that it was functional.
Gearhart says he sought an explanation from the journal's editor-in-chief William Haseltine -chairman of Human Genome Sciences, a Maryland-based biotechnology company -as to how the paper passed editorial muster, but that none was forthcoming. He says he informed Haseltine of his decision to resign in an e-mail on 3 December.
Haseltine defends the decision to publish the paper. "Our reviewers thought it was an advance over what had been done before," he says. "It is not the ultimate word in embryogenesis, but it has not been described as that." The FBI has already indicated that it believes the anthrax culprit is probably based in the United States and recently confirmed that it is investigating US labs capable of producing the high-quality powdery form of the bacteria used in the attacks.
Rosenberg argues, among other things, that tests on the anthrax samples have revealed the presence of a chemical known to have been used in the US process that turns wet slurries of anthrax culture into spores suitable for weapons.
Other scientists involved in bioweapons research have reacted more cautiously. "The general outline has some credence but it is by no means certain," one said.
s

Anthrax evidence implies US culprit
Home-made? Those behind the anthrax spores sent to Congress may have had access to US labs.
